



## USE OF EPIGALLOCATECHIN-GALLATE FOR INHIBITING ANGIOGENESIS

Field of the Invention

5 The invention relates to cosmetic and pharmaceutical treatment methods. More specifically, the invention relates to treatment of angiogenesis-related disorders, particularly skin disorders.

Background of the Invention

10 Angiogenesis, which is the process of producing new capillaries from already existing blood vessels, is a tightly regulated event that does not normally occur in healthy adults, except for certain very specific occurrences such as wound-healing and the female reproductive cycle. It is a complex process that involves a number of steps, including basement membrane degradation, cellular proliferation, migration, and differentiation of endothelial cells, formation of a lumen, and deposition of a new basement membrane. The  
15 regulation of the process is also complex, involving a number of diverse factors, for example, enzymes such as collagenase and protein kinase C, growth factors and signaling molecules such as VEGF and cAMP, and by cell-matrix adhesion molecules.

Angiogenesis is an integral part of the pathogenesis of certain conditions, such as tumor formation, and chronic inflammatory disorders such as rheumatoid arthritis. Angiogenesis  
20 has been associated with chronic inflammatory skin diseases characterized by the neogenesis of capillaries and post-capillary venules due to over-expression of VEGF in epidermal keratinocytes. New vessel growth exacerbates chronic inflammation by facilitating infiltration of monocytes and lymphocytes. In addition to the angiogenic growth factors VEGF and FGF, the cytokines TNF $\alpha$  and IL-1, as well as the lipid  
25 inflammatory mediators PGE<sub>1</sub>, PGE<sub>2</sub>, and PAF have also been implicated in inflammatory angiogenesis. Because there are so many stages in the pathway, however, this provides a number of points in the pathway at which its progress can be stopped. A number of different natural sources of angiogenesis inhibitors have previously been reported; the present invention now presents a new natural source for limiting the progress of  
30 angiogenesis.

### Summary of the Invention

The invention relates to a method of inhibiting angiogenesis in a mammalian tissue which comprises providing to the tissue an effective amount of epigallocatechin gallate(EGCG), epicatechin gallate(ECG), or a combination thereof. The method can be used to treat a number of conditions, such as chronic inflammatory conditions and cancerous tumors. In a particularly preferred embodiment, the EGCG and/or ECG are applied topically to inhibit or reduce angiogenesis associated with various skin conditions.

### Detailed Description of the Invention

EGCG and ECG are two of several polyphenols that occur naturally in green tea, among other natural sources. These two compounds, and green tea generally, have found numerous cosmetic and pharmaceutical uses, including free-radical scavenging, skin whitening, antiinflammatory, and hair coloring. It has now been unexpectedly discovered that these compounds are capable of inhibiting the process of angiogenesis. In particular, it had been initially observed *in vitro* that each of these compounds can inhibit both collagenase and protein kinase C, as well as VEGF-induced migration of endothelial cells, some of the many components that are involved in the angiogenesis pathway. The effect of these inhibitions on angiogenesis has subsequently been confirmed *in vivo* in the chick embryo chorioallantoic membrane assay.

Although several flavonoid compounds have previously been shown to be active in inhibiting angiogenesis(Fotsis et al., Cancer Research 5: 2916-2921, 1997), it has been expressly noted that catechin was inactive in this regard. It is therefore particularly surprising to observe that these specific green tea catechins have any effect on angiogenesis. The catechins employed in the invention may be a EGCG or ECG-enriched fraction of green tea, or it can be any substantially pure EGCG, ECG, or combinations thereof, "substantially pure" being defined as at least 75%, preferably at least 90% free of non-EGCG or ECG compounds.

The effect on angiogenesis of EGCG and ECG is dose-dependent. When evaluated in the chorioallantoic membrane assay, which measures the inhibition of migration of endothelial cells, concentrations of as low as 0.01 mg/ml has a substantial effect on inhibiting this migration, this effect increasing as the concentration is increased, and being

most pronounced at a level of about 1mg/ml. Thus, for practical application for treatment of angiogenesis related disorders, the effective amount of active compound employed will range from about 0.01% to about 10%, preferably about 0.05 to about 5%, most preferably about 0.05 to about 3%, by weight of the total composition. Each compound can be used alone, or in combination with the other.

The catechin component of the composition useful in the methods of the invention can be incorporated into any type of vehicle that is appropriate for the intended mode of administration, which will of course depend upon the condition to be treated. The catechins can be formulated for systemic, e.g., oral or parenteral delivery, or can be formulated for topical delivery. Formulation of these active ingredients is achieved by routine methods, such are described in Remington's Pharmaceutical Sciences, 18<sup>th</sup> ed., 1990, the contents of which are incorporated herein by reference.

The utility of the these green tea catechins in inhibiting angiogenesis makes them very useful in the treatment of a broad variety of conditions, the pathology of which is connected with proliferation of blood vessels, or the migration of blood cells. Such conditions include vascularized solid cancerous tumors, which, as proliferating tissues, are heavily reliant on blood vessels to support their growth. Thus, the EGCG/ECG compositions can be used in a method of treatment of neoplastic growth, either topically or systemically. Additionally, EGCG and/or ECG can be used to prevent angiogenesis caused by chronic inflammatory conditions such as rheumatoid arthritis and psoriasis. The EGCG/ECG compositions can also be used in the treatment of diabetic retinopathy.

In a preferred embodiment, the catechins are used topically to treat skin conditions that are angiogenesis-related. Examples of such conditions include inflammatory skin disorders, such as psoriasis, atopic dermatitis, contact dermatitis, skin cancers such as melanoma, or basal or squamous cell carcinoma, spider veins, and undereye circles. In topical application, the active catechin component is added to the chosen vehicle in the amounts indicated above, and typically applied to the skin in an amount of from about 0.1 mg/cm<sup>2</sup> to 2 mg/cm<sup>2</sup> of skin. Depending upon the condition, the composition may be applied on a temporary schedule, until such time as the condition is relieved, or, with chronic conditions, the compositions can be applied chronically, e.g., a safe and effective amount of a composition containing the mixture is applied to prevent development of the symptoms

of the angiogenesis-related condition, or to relieve a recurring condition. In all cases, topical application of the composition can be performed from about once per week to about 4 or 5 times daily, preferably from about 3 times a week to about 3 times daily, most preferably about once or twice per day. By "chronic" application, it is meant herein that the period of topical application may be over the lifetime of the user, preferably for a period of at least about one month, more preferably from about three months to about twenty years, more preferably from about six months to about ten years, more preferably still from about one year to about five years, which treatment can prevent development of conditions such as undereye shadows and circles, skin inflammation or spider veins.

It may also be desirable to combine other actives with the EGCG/ECG components of the compositions. Examples of other actives that may provide a particular beneficial effect in combination with EGCG or ECG are shark cartilage, phytosphingosine or sphingosine, each of which also has an effect on angiogenesis; skin whiteners, particularly tyrosinase inhibitors, which will supplement the activity of the EGCG/ECG in the treatment of dark circles, to treat or prevent any associated melanization; and antiirritants, to prevent edema that may be associated with any of the treated conditions.

The invention is further illustrated by the following non-limiting examples.

## EXAMPLES

### Example 1

The ability of green tea catechins to inhibit migration of endothelial cells on a collagen matrix is evaluated in a system modeled after the "Boyden chamber" chemotaxis assay. The membrane separating the two chambers is coated with collagen type IV. The top chamber is loaded with human dermal microvascular endothelial cells(HMVEC-d, 250,000 cells/ml) and 5% bovine serum albumin. The bottom chamber contains vascular endothelial growth factor(VEGF, 100 ng/ml) and 5% BSA. Compositions containing an EGCG/ECG combination (77&:23%) in concentrations of from 0.001 to 1mg/ml are added to both the top and bottom chambers, and incubated for 6 hours at 37°C; appropriate vehicle controls are also run. The amount of migrating cells is determined by removing

cells remaining on the surface of the membrane by trypsinization, solubilizing the cells embedded in the membrane and quantitating spectrophotometrically with 1% crystal violet at an optical density of 600nm. The results, shown in Figure 1, indicate that EGCG/ECG inhibits vessel growth in a dose dependent fashion, at concentrations from about 0.01 to 1mg/ml.

### Example 2

The chorioallantoic membrane(CAM) of fertilized chicken eggs has been shown to provide a vascular network suitable for the analysis of anti-angiogenic activity. To test the *in vivo* activity of the green tea catechins, ten fertile white leghorn eggs are incubated at 37°C for 10 days, treated with test sample for 48 hours and evaluated for loss of vasculature compared to controls. On day four, 2.5 ml albumen is removed through a hole drilled at the tip of the egg and then resealed. At this time a rectangular window is cut through the shell directly over the embryo and resealed with tape. On day ten the eggs are removed from the incubator and the chorioallantoic membrane is evaluated for vessel quality; eggs with abnormal or undeveloped membranes are discarded. Test samples over a dose range of 0.01 to 1mg/ml are pipetted(40µl) onto 13 mm round Thermanox coverslips and allowed to air dry. The coverslip is then placed face down onto the CAM and the eggs are returned for the incubator for 48 hours. Following the 48 hour exposure period the CAM of the eggs are evaluated for three criteria in comparison with untreated controls: egg viability, the number of eggs showing prevention of vessel development, and the extent of the area showing loss of vasculature (e.g., 25-50%, 50-75%, or >75%). Phytosphingosine is used as a positive control (showing 100% inhibition at 2.5mg/ml). Table 1 shows the results observed with EGCG/ECG, and indicate that EGCG at higher concentrations inhibit angiogenesis *in vivo*.

TABLE 1

<u>Sample</u>	<u>Dose</u>	<u>% Eggs with loss of vasculature</u>
EGCG/ECG	1.0 mg/ml	30%(25-50% loss of vasculature)
EGCG/ECG	0.5 mg/ml	25%(25-50% loss of vasculature)

EGCG/ECG	0.01 mg/ml	0%
phytosphingosine	2.5 mg/ml	100%(50-100% loss of vasculature)

What we claim is:

1. A method of inhibiting angiogenesis in mammalian tissue which comprises supplying to the tissue a composition comprising an effective amount of epigallocatechin-gallate,  
5 epicatechin gallate or a combination thereof.

2. The method of claim 1 in which the catechin is epigallocatechin-gallate.

3. The method of claim 1 in which the catechin is a combination of epigallocatechin-gallate and epicatechin gallate.  
10

4. The method of claim 1 in which the amount of catechin is from about 0.01 to about 10%.

15 5. The method of claim 1 in which the tissue is a solid tumor.

6. The method of claim 1 in which the tissue is in the skin.

7. A method of treating or preventing an angiogenesis-related condition comprising  
20 applying to the skin a composition containing an effective amount of an epigallocatechin-gallate, epicatechin gallate, or a combination thereof.

8. The method of claim 7 in which the composition comprises epigallocatechin-gallate.

25 9. The method of claim 7 in which the composition comprises a combination of epigallocatechin-gallate and epicatechin gallate.

10. The method of claim 7 in which the amount of catechin is from about 0.01 to about 10%.

11. The method of claim 7 in which the amount of catechin is from about 0.05 to about 5%.

12. The method of claim 7 in which the amount of catechin is from about 0.05 to about 3%.

13. The method of claim 7 in which the condition is a neoplastic condition.

14. The method of claim 13 in which the condition is a squamous cell carcinoma, a basal cell carcinoma, or a melanoma.

15. The method of claim 7 in which the condition is an inflammatory condition.

16. The method of claim 15 in which the condition is psoriasis.

17. The method of claim 7 in which the condition is spider veins or undereye circles.

18. The method of claim 7 in which the composition further comprises an active ingredient selected from the group consisting of an additional angiogenesis inhibitor, a skin whitener, an antiirritant, and combinations thereof.

19. A cosmetic or pharmaceutical composition for topical application to the skin comprising an effective amount of an epigallocatechin-gallate, epicatechin gallate, or a combination thereof, in combination with at least one additional active ingredient selected from the group consisting of angiogenesis inhibitor, a skin whitener, an antiirritant, and combinations thereof.

20. The composition of claim 19 in which the catechin is combined with an angiogenesis inhibitor selected from the group consisting of shark cartilage, phytosphingosine, or sphingosine.

21. The composition of claim 19 in which the catechin is combined with a skin whitener.
22. The composition of claim 19 in which the catechin is combined with an antiirritant.
- 5 23. The composition of claim 19 in which the amount of catechin is from about 0.01 to about 10% by weight of the total composition.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 01/01019

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/353 A61K45/06 A61K45/08 A61P35/00 A61P43/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, MEDLINE, BIOSIS, PAJ, CHEM ABS Data, SCISEARCH, PASCAL, AIDSLINE, CANCERLIT

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ALBINI ET AL: " Old drugs as novel angiogenesis inhibitors: Preclinical studies with NAC, hCG, EGCG and somatostatin" CLINICAL & EXPERIMENTAL METASTASIS, vol. 17, 1999, page 738 XP002167145 * S16 *	1-5
Y	abstract the whole document ----- -/--	6-23

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

11 May 2001

Date of mailing of the international search report

12/06/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040. Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Uiber, P

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 01/01019

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	F.Y. TANG: " Green tea polyphenols and vitamin E inhibit angiogenesis by suppressing IL-8" FREE RADICAL BIOLOGY & MEDICINE , vol. 27, no. suppl.1, 1999, page s149 XP000998584 * no. 456 * abstract	1-5
Y	the whole document	6-23
X	US 4 517 175 A (IWABUCHI HIDETOSHI ET AL) 14 May 1985 (1985-05-14) * Ex.3; claims 1-9 *	19,22,23
X	US 5 616 332 A (HERSTEIN MORRIS) 1 April 1997 (1997-04-01) * col.4, l.10-45, espec. l.15; col.8, l.19; Tables 1-4; claims 1-4 *	19,20, 22,23
X	EP 0 853 943 A (SUNTORY LTD) 22 July 1998 (1998-07-22) * claims 10-12,15-16; p.5, l.27 *	19,21-23
P,X	WO 00 47193 A (KAROLINSKA INNOVATIONS AB ;CAO YIHAI (SE)) 17 August 2000 (2000-08-17) * p.6, l.3-4; p.13, l.18-20; p.15, l.9; claims 1-9; Fig.2 *	1-23
X	WO 00 00194 A (PERSHADSINGH HARRIHAR A ;LEVY DANIEL E (US); PHOTOGENESIS INC (US)) 6 January 2000 (2000-01-06) * p.15, l.28-29; p.19, l.16 *	19
Y	DATABASE WPI Section Ch, Week 199429 Derwent Publications Ltd., London, GB; Class B02, AN 1994-238610 XP002167146 & JP 06 172122 A (IENOYA HONTEN KK), 21 June 1994 (1994-06-21) abstract	19-23
Y	WO 96 37201 A (ARCH DEV CORP ;LIANG THEMING (US); LIAO SHUTSUNG (US)) 28 November 1996 (1996-11-28) * p.9, l.28; p.17, l.12; p.31, l.5-11; p.31, l.5-11; p.91, l.25; p.92, l.13; claims 5-6 *	1-23
X	EP 0 742 012 A (KUREHA CHEMICAL IND CO LTD) 13 November 1996 (1996-11-13) * p.11, l.55-56; p.12, l.54-p.13, l.3; claim 7 *	1-23
	--- -/--	

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/01019

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 306 486 A (MCCOOK JOHN P ET AL) 26 April 1994 (1994-04-26) * Ex.1-8; Claims 1-5 *	19,22,23
X	MCCARTY M F: "POLYPHENOL-MEDIATED INHIBITION OF AP-1 TRANSACTIVATING ACTIVITY MAY SLOW CANCER GROWTH BY IMPEDING ANGIOGENESIS AND TUMOR INVASIVENESS" MEDICAL HYPOTHESES, EDEN PRESS, PENRITH, US, vol. 50, June 1998 (1998-06), pages 511-514, XP000957651 ISSN: 0306-9877 abstract	1-23
X	CAO Y ET AL: "ANGIOGENESIS INHIBITED BY DRINKING TEA" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 398, 1 April 1999 (1999-04-01), page 381 XP000953295 ISSN: 0028-0836 * 1st col., 1st par; 3rd col., last par. *	1-23
Y	FUJIKI H ET AL: "Japanese green tea as a cancer preventive in humans" NUTRITION REVIEWS, US, ALLEN PRESS, LAWRENCE, KS, vol. 54, no. 11, PART 02, November 1996 (1996-11), pages S67-S70, XP002102790 ISSN: 0029-6643 abstract	1-23
Y	TANIGUCHI S ET AL: "Effect of (-)- epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines" CANCER LETTERS, US, NEW YORK, NY, vol. 65, no. 1, 31 July 1992 (1992-07-31), pages 51-54, XP002102792 ISSN: 0304-3835 * abstract; p.54, Discussion *	1-23
Y	DE 196 27 344 A (VITASYN GMBH ENTWICKLUNG & VER) 8 January 1998 (1998-01-08) * p.3, 1.25-28; claims 25-28 *	1-23

# INTERNATIONAL SEARCH REPORT

Information on patent family members

In .ational Application No

PCT/US 01/01019

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4517175	A	14-05-1985	JP 2519024 B JP 59051209 A CA 1201978 A DE 3320539 A ES 523033 D ES 8503248 A FR 2527927 A GB 2121281 A, B	31-07-1996 24-03-1984 18-03-1986 08-12-1983 16-02-1985 01-06-1985 09-12-1983 21-12-1983
US 5616332	A	01-04-1997	EP 0716589 A WO 9503028 A	19-06-1996 02-02-1995
EP 0853943	A	22-07-1998	JP 10175874 A	30-06-1998
WO 0047193	A	17-08-2000	AU 2567300 A	29-08-2000
WO 0000194	A	06-01-2000	AU 4713499 A	17-01-2000
JP 6172122	A	21-06-1994	NONE	
WO 9637201	A	28-11-1996	US 5605929 A AU 5922096 A CA 2221236 A CN 1190888 A EP 0827401 A JP 11507022 T	25-02-1997 11-12-1996 28-11-1996 19-08-1998 11-03-1998 22-06-1999
EP 0742012	A	13-11-1996	JP 8301781 A JP 8301757 A JP 2892300 B JP 8301784 A JP 3003978 B JP 9012459 A JP 9040556 A JP 2933511 B JP 9040553 A AU 689036 B AU 5214096 A CA 2175985 A	19-11-1996 19-11-1996 17-05-1999 19-11-1996 31-01-2000 14-01-1997 10-02-1997 16-08-1999 10-02-1997 19-03-1998 19-12-1996 11-11-1996
US 5306486	A	26-04-1994	AU 6141994 A WO 9420066 A ZA 9401172 A	26-09-1994 15-09-1994 21-08-1995
DE 19627344	A	08-01-1998	DE 29623606 U	10-06-1999